Literature DB >> 1974249

Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.

H Singh1, J I Hunt, B Vitiello, G M Simpson.   

Abstract

In an attempt to prospectively validate the existence of supersensitivity psychosis (SSP), five schizophrenic patients meeting Chouinard's criteria for SSP and five non-SSP schizophrenic controls had neuroleptic treatment withdrawn for 2 weeks under double-blind conditions. The sudden worsening of psychotic symptoms and tardive dyskinesia postulated in the SSP group was not observed on the Brief Psychiatric Rating Scale, the Clinical Global Impressions scale, and the Abbreviated Dyskinesia Rating Scale. In conclusion, the authors' pilot data do not seem to support the existence of SSP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974249

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

Review 2.  Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia.

Authors:  M F Bristow; S R Hirsch
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 3.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

Review 4.  Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.

Authors:  Yasunori Oda; Nobuhisa Kanahara; Masaomi Iyo
Journal:  Int J Mol Sci       Date:  2015-12-17       Impact factor: 5.923

5.  Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder.

Authors:  Ravi Philip Rajkumar
Journal:  Case Rep Psychiatry       Date:  2014-11-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.